Impacted: Health plan clients and Prime's mid-market book of business

What you need to know

Effective July 24, 2025, Accredo will no longer stock low wholesale acquisition cost (WAC) Hyrimoz (adalimumab-adaz) by Sandoz Inc. Existing Hyrimoz users will be transitioned by Accredo to a preferred biosimilar option which now also includes Yuflyma (adalimumab-aaty) (low WAC) by Celltrion, Inc. This change is part of Accredo’s ongoing product portfolio evaluation. Accredo continues to stock all other Prime Therapeutics (Prime) preferred Humira biosimilars. 

No action is required from clients at this time. 
 

Overview

Accredo has informed Prime that it will discontinue stocking Hyrimoz. This decision reflects Accredo’s strategy to streamline its biosimilar offerings while maintaining access to cost-effective treatment options. Accredo will continue to stock other Prime preferred adalimumab biosimilar products, including Yuflyma, Simlandi (adalimumab-ryvk) by Teva/Alvotech and Hadlima (adalimumab-bwwd) by Samsung/Organon. 

Prime will continue to monitor pharmacy network changes and provide updates as needed to support our clients and members.  
 

Next steps

Accredo is proactively managing the transition process to ensure a smooth member experience: 

• Prescriber outreach: Accredo will contact prescribers 14 days prior to a member’s refill to allow time for a new prescription. 
• Member notification: Members will be notified by phone that Hyrimoz is no longer available. If there is a delay in prescriber response, members will receive a follow-up notification. 
• Prescription fulfillment: Once the new prescription is received, Accredo will schedule the order and assist with enrollment in the new copay assistance program (if eligible). 
• Clinical support: Accredo’s telephonic nursing team will reach out to ensure members are comfortable with the new product and reinforce adherence for optimal outcomes. 

Prime will continue to share additional information as we learn more.

FAQs

In an effort to keep clients informed, Prime has compiled an FAQ providing more details on changes to Accredo’s adalimumab biosimilar availability. 

Questions

Please reach out to your Prime account team representative.